The legacy success of sildenafil has undeniably influenced the healthcare landscape. However, putting money in companies heavily dependent on biosimilars and the waning patent exclusivity surrounding this https://nanobookmarking.com/story21287752/the-blue-pill-and-drugmakers-a-risky-opportunity